Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth.
Anna HanDzmitry MukhaVivian ChuaTimothy J PurwinManoela TiagoBhavik ModasiaUsman BaqaiJenna L AumillerNelisa BechtelEmily HunterMeggie DanielsonMizue TeraiPhilip B WedegaertnerTakami SatoSolange LandrevilleMichael A DaviesStefan KurtenbachJ William HarbourZachary T SchugAndrew E AplinPublished in: Cancers (2023)
Uveal melanoma (UM) displays a high frequency of metastasis; however, effective therapies for metastatic UM are limited. Identifying unique metabolic features of UM may provide a potential targeting strategy. A lipid metabolism protein expression signature was induced in a normal choroidal melanocyte (NCM) line transduced with GNAQ (Q209L), a driver in UM growth and development. Consistently, UM cells expressed elevated levels of fatty acid synthase (FASN) compared to NCMs. FASN upregulation was associated with increased mammalian target of rapamycin (mTOR) activation and sterol regulatory element-binding protein 1 (SREBP1) levels. FASN and mTOR inhibitors alone significantly reduced UM cell growth. Concurrent inhibition of FASN and mTOR further reduced UM cell growth by promoting cell cycle arrest and inhibiting glucose utilization, TCA cycle metabolism, and de novo fatty acid biosynthesis. Our findings indicate that FASN is important for UM cell growth and co-inhibition of FASN and mTOR signaling may be considered for treatment of UM.
Keyphrases
- cell cycle arrest
- high frequency
- fatty acid
- cell proliferation
- signaling pathway
- cell death
- binding protein
- transcranial magnetic stimulation
- squamous cell carcinoma
- small cell lung cancer
- transcription factor
- induced apoptosis
- radiation therapy
- poor prognosis
- optical coherence tomography
- type diabetes
- risk assessment
- endothelial cells
- locally advanced
- blood glucose
- skin cancer
- cell wall